Researcher
Benedicte De Winter
- Research Expertise:- Visceral pain - Inflammation - ileus - irritable bowel syndrome - IBS - inflammatory bowel disease - IBD - sepsis - experimental and clinical translational research - medisch vaardighedenonderwijs
- Keywords:VISCERAL PAIN, SEPSIS, IRRITABLE BOWEL SYNDROME, INFLAMMATION, INFLAMMATORY BOWEL DISEASE, Medicine
- Disciplines:Gastro-enterology, Inflammation, Pathophysiology
- Research techniques:- in vivo animal models of IBS, IBD and sepsis - visceromotor response and afferent neuronal activity - motility and sensitivity assays - inflammation measurements - Elisa, flowcytometry - vaardigheden, portfolio, stationsproeven
- Users of research expertise:- research labs - pharmaceutical industry - (bio-, para-) medical schools
Affiliations
- Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Responsible
From1 Oct 2013 → Today - Laboratory Experimental Medicine and Pediatrics (LEMP) (Research group)
Member
From1 Oct 2003 → 30 Sep 2013 - Primary and interdisciplinary care Antwerp (ELIZA) (Research group)
Member
From1 Oct 2003 → 30 Sep 2008
Projects
1 - 10 of 32
- Crosstalk between MUC13 signalling and the mucosal microbiota in gastric cancer development.From1 Jan 2024 → TodayFunding: Nonprofit institution or equivalents
- Automation of a mucin mRNA isoform-based biomarker platform to monitor patients with inflammatory bowel diseases.From1 Sep 2023 → TodayFunding: IOF - technology validation in lab
- REspiratory Virus Repository ANTwerp (ReViRAnt).From1 Jan 2023 → TodayFunding: Flemish Resilience. Government of Flanders Recovery Plan - strengthening R&D
- Turning the understanding of inflammation-related pathology into new biomarkers and treatments using next-generation technologies and high-throughput data mining.From1 Nov 2022 → TodayFunding: BOF - postdoctoral mandates
- A mucin mRNA isoform-based biomarker assay to improve treatment response in patients with inflammatory bowel diseases.From1 Sep 2022 → 31 Aug 2023Funding: IOF - technology validation in lab
- High-end comprehensive GCxGC-QTOF-MS research facility for volatile and semivolatile compounds (GALILEO).From1 Jun 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Assessing health effects of air pollution by non-invasive exhaled breath analysis (ALERT).From1 Jun 2021 → 31 May 2023Funding: Provinces
- Mucin isoform-microbiome crosstalk shaping the course of COVID-19: a help in patient stratification?From1 Nov 2020 → 31 Oct 2021Funding: FWO Special Call for Covid-19 research projects, BOF - projects
- Study of the mechanisms involved in MUC1/MUC13-induced intestinal barrier disruption during inflammatory bowel diseases: a translational approach.From1 Nov 2020 → TodayFunding: FWO junior postdoctoral fellowship
- Functional characterization of human mast cells and basophils in the pathophysiology of diarrhea-predominant irritable bowel syndrome.From1 Oct 2020 → 30 Sep 2022Funding: FWO fellowships
Publications
11 - 20 of 164
- IL-22-activated MUC13 impacts on colonic barrier function through JAK1/STAT3, SNAI1/ZEB1 and ROCK2/MAPK signaling(2023)
Authors: Tom Breugelmans, Wout Arras, Baptiste Oosterlinck, Aranzazu Jauregui, Michaël Somers, Bart Cuypers, Kris Laukens, Joris De Man, Heiko De Schepper, Benedicte De Winter, et al.
Pages: 1 - 25 - Single-day and multi-day exposure to orogastric gavages do not affect intestinal barrier function in mice(2023)
Authors: Nikita Hanning, Rosanne Verboven, Joris De Man, Hannah Ceuleers, Heiko De Schepper, Annemieke Smet, Benedicte De Winter
Pages: G281 - G294 - Zonated quantification of immunohistochemistry in normal and steatotic livers(2023)
Authors: Cédric Peleman, Winnok De Vos, Isabel Pintelon, Ann Driessen, Annelies Van Eyck, Christophe Van Steenkiste, Luisa Vonghia, Joris De Man, Benedicte De Winter, Tom Vanden Berghe, et al.
Pages: 1035 - 1045 - Mucin-microbiome signatures shape the tumor microenvironment in gastric cancer(2023)
Authors: Baptiste Oosterlinck, Hannah Ceuleers, Wout Arras, Joris De Man, Karen Geboes, Heiko De Schepper, Marc Peeters, Sarah Lebeer, Jurgita Skieceviciene, Georgina L. Hold, et al.
Pages: 1 - 18 - How can peer teaching influence the development of medical students? A descriptive, longitudinal interview study(2023)
Authors: Marijke Avonts, Katrien Bombeke, Nele Michels, Olivier Vanderveken, Benedicte De Winter
Pages: 1 - 12 - Pathophysiological mechanisms in irritable bowel syndrome(2023)
Authors: Kathleen Van Malderen, Heiko De Schepper, Vito Sabato, Benedicte De Winter
Number of pages: 207 - Urinary epidermal growth factor reflects vascular health in boys with either obesity or type 1 diabetes(2023)
Authors: Kristien Ledeganck, Annelies Van Eyck, Eline Vermeiren, Benedicte De Winter, Stijn Verhulst, Kim Van Hoorenbeeck, Annick France, Hilde Dotremont, Marieke den Brinker
Pages: 1 - 16 - Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients(2022)
Authors: Arno Verleye, Steven Abrams, Rania Bougrea, Annick Massart, Lissa Pipeleers, Karl Martin Wissing, Kevin Ariën, Benedicte De Winter, Pierre Van Damme, Daniel Abramowicz, et al.
Pages: 1566 - 1575 - Does peer teaching improve academic results and competencies during medical school? A mixed methods study(2022)
Authors: Marijke Avonts, Nele Michels, Katrien Bombeke, Olivier Vanderveken, Benedicte De Winter
Pages: 1 - 8 - Gut microbial β-glucuronidases regulate host luminal proteases and are depleted in irritable bowel syndrome(2022)
Authors: Adam L. Edwinson, Lu Yang, Stephanie Peters, Nikita Hanning, Patricio Jeraldo, Pratik Jagtap, Joshua B. Simpson, Tzu-Yi Yang, Praveen Kumar, Subina Mehta, et al.
Pages: 680 - 694
Patents
1 - 9 of 9
- Method for determining the severity and prognosis of rsv infection (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Mucins and isoforms thereof in diseases characterized by barrier dysfunction (Inventor)
- Method for determining the severity and prognosis of RSV infection (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Mucin isoforms in diseases characterized by barrier dysfunction (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
Linked dataset
1 - 1 of 1